Not Tagged
Not Tagged
['lung']
in its first time on a bigger stage at #asco22, cullinan thinks it has the data to distinguish itself from the only other approved drugs for egfr exon 20 insertion mutations, which are found in 2% to 3% of patients with non-small cell lung cancer. 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs